FDA approves new drug for advanced prostate cancer - KFDA - NewsChannel 10 / Amarillo News, Weather, Sports

FDA approves new drug for advanced prostate cancer

WASHINGTON (AP) — The Food and Drug Administration said Friday it approved the pill Xtandi for men with advanced prostate cancer that has returned or spread despite major medical intervention.

The drug, developed by Medivation, is indicated for patients who have already tried the chemotherapy drug docetaxel and testosterone-limiting interventions. Doctors use drugs or surgery to limit testosterone, which can spur growth of prostate tumors.

More than 241,000 men will be diagnosed with prostate cancer this year and 28,170 will die from the disease, according to an estimate by the National Cancer Institute.

Regulators approved Xtandi based on a study of 1,200 patients with advanced prostate cancer who received the drug or a placebo. Patients taking Xtandi survived 18.4 months after beginning treatment, or nearly 5 months longer than patients taking placebo, who survived 13.6 months, on average.

The most common side effects seen with the drug include fatigue, back pain, diarrhea, headache and dizziness.

Xtandi was developed by San Francisco-based Medivation with financial and research support for Japanese drugmaker Astellas Pharmaceuticals. The companies will share the marketing costs and profits from the drug.

Shares of Medivation rose $1.37, or 11.4 percent, to $98.79 in trading Friday. Astellas Pharma Inc. rose 70 cents to $49.30.

  • Health WatchMore>>

  • Legendary wildcatter Boone Pickens takes a Texas-sized fall

    Legendary wildcatter Boone Pickens takes a Texas-sized fall

    Friday, July 21 2017 8:18 AM EDT2017-07-21 12:18:33 GMT
    Friday, July 21 2017 4:49 PM EDT2017-07-21 20:49:07 GMT
    T. Boone Pickens, who is suffering from a series of strokes, took at "Texas-sized fall" that put him in the hospital last week.
    T. Boone Pickens, who is suffering from a series of strokes, took at "Texas-sized fall" that put him in the hospital last week.
  • RECALL ALERT: Activity toys recalled due to choking hazard

    RECALL ALERT: Activity toys recalled due to choking hazard

    Friday, July 21 2017 9:54 AM EDT2017-07-21 13:54:09 GMT

    Manhattan Toy recalls activity toys due to choking hazard. The colored plastic tubes on the product can become brittle and break into small pieces, posing a choking hazard to infants. The Winkel Colorburst teething and activity toy has multi-color plastic tubing inserted into a plastic cube with rattle beads inside. The model number and lot code are printed on the center of the cube and on the hang-tag and product packaging near the UPC code. Only activity balls with the follow...

    Manhattan Toy recalls activity toys due to choking hazard. The colored plastic tubes on the product can become brittle and break into small pieces, posing a choking hazard to infants. The Winkel Colorburst teething and activity toy has multi-color plastic tubing inserted into a plastic cube with rattle beads inside. The model number and lot code are printed on the center of the cube and on the hang-tag and product packaging near the UPC code. Only activity balls with the follow...

  • Don't let swimmer's ear ruin your summer fun

    Don't let swimmer's ear ruin your summer fun

    Thursday, July 20 2017 5:55 PM EDT2017-07-20 21:55:36 GMT
    Thursday, July 20 2017 6:04 PM EDT2017-07-20 22:04:02 GMT
    Swimmer's ear can happen in any season, but becomes more common during warmer months. (Source: CNN)Swimmer's ear can happen in any season, but becomes more common during warmer months. (Source: CNN)

    Despite its name, you don't have to spend time at a beach or pool to pick up the infection.

    Despite its name, you don't have to spend time at a beach or pool to pick up the infection.

Powered by Frankly